Format

Send to

Choose Destination
Clin Interv Aging. 2019 Feb 19;14:389-398. doi: 10.2147/CIA.S168687. eCollection 2019.

Current and emerging biomarkers of frailty in the elderly.

Saedi AA1,2, Feehan J1,2, Phu S1,2, Duque G1,2.

Author information

1
Australian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and Western Health, St Albans, Melbourne, VIC, Australia, gustavo.duque@unimelb.edu.au.
2
Department of Medicine, Western Health, Melbourne Medical School, University of Melbourne, St Albans, Melbourne, VIC, Australia, gustavo.duque@unimelb.edu.au.

Abstract

The term "frailty" is used to describe a subset of older adults who appear weaker and more vulnerable than their age-matched counterparts, despite having similar comorbidities, demography, sex, and age. The diagnosis of frailty is usually clinical and based on specific criteria, which are sometimes inconsistent. Therefore, there is an increasing need to identify and validate robust biomarkers for this condition. In this review, we summarize current evidence on the validity and practicality of the most commonly used biomarkers for frailty, while also comparing them with new upcoming strategies to identify this condition.

KEYWORDS:

COP cells; biomarkers; disability; elderly; frailty; mesenchymal stem cells

PMID:
30863033
PMCID:
PMC6388773
DOI:
10.2147/CIA.S168687
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center